Geller R B, Saral R, Karp J E, Santos G W, Burke P J
Johns Hopkins Oncology Center, Baltimore, Maryland.
Leukemia. 1990 May;4(5):313-5.
Adult acute myelocytic leukemia (AML) is a curable disease in responsive patients with aggressive treatment in remission. Over the past decade at the Johns Hopkins Oncology Center, AML has been treated with either allogeneic bone marrow transplantation or with intensive timed sequential treatment using high dose cytarabine in remission. With either treatment modality comparable cure rates were obtained. The role, if any, of randomized trials to adequately determine the preferred treatment for appropriate patients has yet to be defined.
成人急性髓细胞白血病（AML）对于缓解期接受积极治疗的反应性患者而言是一种可治愈的疾病。在过去十年里，约翰霍普金斯肿瘤中心对AML患者采用了异基因骨髓移植或在缓解期使用大剂量阿糖胞苷进行强化定时序贯治疗。两种治疗方式都取得了相当的治愈率。对于充分确定适合患者的首选治疗方法而言，随机试验的作用（若有）尚未明确。
